Completed PHASE1 INTERVENTIONAL NCT00002136

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Sponsor: Daiichi Pharmaceuticals

Conditions HIV Infections Sarcoma, Kaposi

Updated 5 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates HIV Infections and Sarcoma, Kaposi and is currently completed. Daiichi Pharmaceuticals leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Pharmaceuticals

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States